SABCS 2025: Latest developments in multigene testing in early breast cancer

Multimodal AI model augments Oncotype DX in predicting distant recurrence in HR+/HER2 node negative BC

Non-TBI conditioning achieves positive results in MRD-negative CAYA B-ALL undergoing allogeneic HCT

Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma

Black patients show inferior survival despite similar cytogenetics and treatment response